Journal of Antimicrobial Chemotherapy (1992) 30, 47-55
© 1992 The British Society for Antimicrobial Chemotherapy
research-article |
The antimicrobial susceptibility of Moraxella catarrhalis isolated in England and Scotland in 1991
Department of Medical Microbiology, The London Hospital Medical College Turner Street, London El 2AD, UK
Received 11 November 1991; accepted 12 February 1992
*Corresponding author.
Between 1 January and 31 March 1991, 20 laboratories in England and Scotland sent a total of 413 consecutive clinical isolates of Moraxella catarrhalis to The London Hospital Medical College (LHMC). After confirmation of identity, the susceptibility of all isolates to 11 antimicrobial agents was determined. Of the 375 (90·8%) isolates which were found at LHMC to be ß-lactamase-positive, 174 produced zones of inhibition around 2 µg ampicillin disc which were 
20 mm in diameter and 252 were inhibited by 
0·5 mg/L of ampicillin. However, 71 of these 375 had been reported to be ampicillin-susceptible by peripheral centres. While ß-lactamase had not been detected in 35 of these 71 isolates, the other 36 had been reported to be ampicillin-susceptible and ß-lactamase-positive. All 38 ß-lactamase negative isolates produced zones 30 mm in diameter and were inhibited by 0·06 mg/L of ampicillin. No M. catarrhalis isolate was found to be resistant to co-amoxiclav, tetracycline, chloramphenicol or cefaclor. Two strains showed intermediate susceptibility to erythromycin (MIC 1 mg/L) and 27 required 32 mg/L of sulphamethoxazole for inhibition. Resistance to trimethoprim was uniform (MICs 2–128 mg/L). Two isolates showed intermediate susceptibility to cefixime (MIC 2 mg/L) but none was resistant to the new oral cephalosporin cefetamet or to the oral carbacephem loracarbef. Aprt from ß-lactamase production and inherent resistance to trimethoprim. the results indicate that there are few problems of acquired resistance to antimicrobials amongst M. catarrhalis isolates in England and Scotland.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  J. M. Bell, J. D. Turnidge, and R. N. Jones Development of a Disk Diffusion Method for Testing Moraxella catarrhalis Susceptibility Using Clinical and Laboratory Standards Institute Methods: a SENTRY Antimicrobial Surveillance Program Report J. Clin. Microbiol., July 1, 2009; 47(7): 2187 - 2193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Morrissey, K. Maher, L. Williams, J. Shackcloth, D. Felmingham, R. Reynolds, and on behalf of the BSAC Working Parties on Resistanc Non-susceptibility trends among Haemophilus influenzae and Moraxella catarrhalis from community-acquired respiratory tract infections in the UK and Ireland, 1999-2007 J. Antimicrob. Chemother., November 1, 2008; 62(suppl_2): ii97 - ii103. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. M. Verduin, C. Hol, A. Fleer, H. van Dijk, and A. van Belkum Moraxella catarrhalis: from Emerging to Established Pathogen Clin. Microbiol. Rev., January 1, 2002; 15(1): 125 - 144. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X.-X. Gu, J. Chen, S. J. Barenkamp, J. B. Robbins, C.-M. Tsai, D. J. Lim, and J. Battey Synthesis and Characterization of Lipooligosaccharide-Based Conjugates as Vaccine Candidates for Moraxella (Branhamella) catarrhalis Infect. Immun., May 1, 1998; 66(5): 1891 - 1897. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. E. Paker, J. A. Graham, A. M. Rauch, and J. J. Collins Cefuroxime Axetil in the Treatment of Sinusitis: A Review Arch Fam Med, February 1, 1994; 3(2): 165 - 175. [Abstract] [PDF]
|
|